

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
REGISTRATION OF RECOMBINANT COVID-19 VACCINE
(ADENOVIRUS TYPE 5 VECTOR) AS A PHARMACEUTICAL
PRODUCT IN HONG KONG

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, the Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia®) developed by the Group, has recently obtained a certificate of registration from the Pharmacy and Poisons Board of Hong Kong and successfully registered as a pharmaceutical product in Hong Kong.

The approval is in accordance with the Pharmacy and Poisons Ordinance (Cap. 138 of the Laws of Hong Kong). After the successful registration as a pharmaceutical product in Hong Kong, the Group's Convidecia® is not limited to emergency use, and individuals with willingness to be vaccinated are able to receive vaccination at medical institutions or clinics in Hong Kong upon prescription by a medical practitioner.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 9, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.